NEW YORK, May 29 – Over the past six months, with genomics companies scrambling over themselves to stake out a piece of the profits from drug discovery, it shouldn’t be too much of a surprise that Sequenom followed suit.
Registering provides access to this and other free content.
Already have an account?Login Now.
The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.
The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.
The first Reproducibility Project: Cancer Biology papers show mixed results.
In Nature this week: mobile phone-based targeted DNA sequencing, and more.